Decipher Labs Limited
BSE: DECIPHER · Pharmaceuticals · sector
₹5.20BSE close 2026-10-26
Key numbers
Market cap₹5 cr
Price₹5.20
52w high / low₹11 / ₹5
P/E1.7xSector median 27.9x
P/B0.6xSector median 2.9x
Book value₹8.2
Dividend yield–Sector median 0.48%
ROE-4.0%Sector median 11.7%
ROCE-28.0%Sector median 12.3%
OPM-16.4%Sector median 14.0%
Debt / equity0.06xSector median 0.16x
EV/EBITDA–Sector median 18.6x
Interest cover–
Current ratio0.22x
Sales growth 3y+158.9%Sector median +9.6%
Profit growth 3y–Sector median +13.3%
PEG–
Last 12 months to Jun 2026, Consolidated. "Sector median" = middle value of 185 companies in Pharmaceuticals (P/E median leaves out loss-making companies). Tap ? for what a number means.
Things to know
- Cash ₹0 cr vs borrowings ₹0 cr (FY26): borrowings are higher by ₹0 cr.
- Net loss in 4 of the last 6 quarters.
- No dividend in the last 5 financial years.
- Price ₹5.20 on 2026-10-26: -52.7% from the 52-week high, +8.1% from the 52-week low.
Plain facts from the filings, built by the same fixed rules for every company. A line appears only when the data for it is available. Not a view on the stock.
Charts
Weekly close · high ₹16.96 · low ₹5.20
RevenueNet profit
RevenueNet profit
Quarterly results
| ₹ cr | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|
| Revenue | 4 | 3 | 4 | 3 | 4 | 2 |
| EBITDA | -7 | -3 | 0 | -0 | 0 | -2 |
| OPM % | -188.0% | -113.7% | 2.8% | -13.1% | 6.4% | -89.2% |
| Other income | 1 | 0 | 0 | 0 | 0 | 0 |
| Net profit | -4 | -3 | 0 | -1 | -0 | 0 |
| EPS (₹) | 4.07 | 3.39 | 0.02 | 0.53 | 0.35 | 2.16 |
| Revenue YoY | +2.9% | -17.5% | ||||
| Profit YoY | – | – |
Consolidated figures where filed. Latest quarter Jun 2026.
Profit & loss (yearly)
| ₹ cr | FY22 | FY23 | FY24 | FY25 | FY26 | TTM |
|---|---|---|---|---|---|---|
| Revenue | 1 | 1 | 4 | 23 | 14 | 14 |
| EBITDA | 0 | -3 | 0 | -7 | -3 | -2 |
| Net profit | 0 | -3 | 0 | -5 | -3 | -1 |
| EPS (₹) | 0.36 | -2.59 | 0.02 | 5.03 | 3.05 | 3.06 |
| Revenue growth | -18.2% | +335.8% | +540.5% | -37.9% | – | |
| Profit growth | -827.8% | – | -25,500.0% | – | – | |
| Dividend / share (₹) | – | – | – | – | – |
| Compounded growth | 3 years | 5 years | Last 12 months |
|---|---|---|---|
| Sales | +158.9% | – | – |
| Net profit | – | – | – |
| EPS | – | – | – |
| Share price | – | -41.6% (2y) | -45.2% |
Balance sheet
| ₹ cr | FY25 | FY26 |
|---|---|---|
| Shareholders' equity | 23 | 8 |
| Borrowings | 0 | 0 |
| Cash & equivalents | 3 | 0 |
| Total assets | 26 | 9 |
| Fixed assets | 1 | 0 |
| Capital work in progress | 0 | – |
| Investments | 0 | 9 |
| Receivables | 4 | 0 |
| Inventory | 0 | 0 |
| Payables | 1 | 0 |
Year-end figures from the March annual filing.
Cash flow
| ₹ cr | FY25 | FY26 |
|---|---|---|
| Cash from operations | -10 | -2 |
| Cash from investing | 3 | -0 |
| Cash from financing | 0 | 0 |
| Capex | 0 | 0 |
| Free cash flow | -10 | -2 |
Free cash flow = cash from operations − capex.
Ratios by year
| ₹ cr | FY25 | FY26 |
|---|---|---|
| ROE % | -22.2% | -37.4% |
| ROCE % | -27.6% | -42.1% |
| Debtor days | 68 | 1 |
| Inventory days | 0 | 2 |
| Payable days | 628 | 58 |
| Cash conversion cycle (days) | -560 | -55 |
| Working capital days | 293 | -15 |
Peers in Pharmaceuticals
| Company | Market cap | P/E | P/B | ROE | ROCE | OPM | Sales 3y | Div yield |
|---|---|---|---|---|---|---|---|---|
| SUNPHARMA | ₹4,17,478 cr | 34.5x | 5.0x | 15.5% | 18.7% | 28.6% | +10.0% | 0.94% |
| DIVISLAB | ₹2,39,825 cr | 82.1x | 14.3x | 18.4% | 23.0% | 34.7% | +10.8% | 0.34% |
| TORNTPHARM | ₹1,53,999 cr | 72.7x | 18.4x | 27.3% | 15.1% | 32.3% | +13.3% | 0.84% |
| ZYDUSLIFE | ₹1,15,808 cr | 25.9x | 4.3x | 17.7% | 16.8% | 27.2% | +16.4% | 0.95% |
| LAURUSLABS | ₹1,11,232 cr | 101.6x | 21.0x | 22.4% | 20.8% | 28.0% | +4.1% | 0.08% |
| CIPLA | ₹1,09,464 cr | 32.5x | 3.2x | 10.3% | 13.2% | 17.7% | +7.4% | 1.18% |
| DRREDDY | ₹1,09,460 cr | 33.9x | 2.9x | 9.0% | 10.1% | 15.5% | +11.0% | 0.61% |
| MANKIND | ₹95,486 cr | 46.7x | 5.9x | 13.4% | 13.8% | 25.1% | +17.7% | 0.04% |
| AUROPHARMA | ₹91,489 cr | 24.9x | 2.4x | 10.5% | 12.8% | 20.0% | +10.6% | 0.26% |
| DECIPHER | ₹5 cr | 1.7x | 0.6x | -4.0% | -28.0% | -16.4% | +158.9% | – |
Business segments (2026-06-30)
| Segment | Revenue | Share | EBIT | Margin |
|---|---|---|---|---|
| Consultancy Services | ₹2 cr | 99.8% | ₹-2 cr | -90.5% |
| Manufacturing and Trading of Pharmaceutical drugs | ₹0 cr | 0.2% | ₹0 cr | -80.0% |
Documents
Links go to the original files on the exchange website.
About the company
| Sector | Healthcare |
| Industry | Pharmaceuticals |
| Sub-industry | Pharmaceuticals |
| Symbol | DECIPHER |
| BSE code | 524752 |
| ISIN | INE643N01012 |
| Face value | ₹10.0 |
| Incorporated | – |
| Website | – |
| Plants (India / abroad) | – |
Data built 2026-10-24 from BSE company filings (inline XBRL: Integrated Filing - Finance) + BSE results summary for earlier years; price = BSE close 2026-10-26.